News

Johnson & Johnson (J&J) has obtained approval from the US Food and Drug Administration (FDA) for a revised dosing schedule of Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), introducing a once-monthly administration option for patients with advanced, epidermal growth factor receptor...

On February 17, 2026, GSK plc announced that the European Commission approves Exdensur - depemokimab in two indications - As an add-on maintenance treatment when it comes to critical asthma with type 2 inflammation that stands characterised by a blood eosinophil...

In a move that is sure to create a stir within the Asia pharma circle, Sanofi Healthcare India - SHIPL is going ahead and expanding its GCC- global capability centre in Hyderabad, Telangana State with another 2.7 lakh sq.ft....

Gilead Sciences has added another synthetic lethal asset to its oncology portfolio, agreeing to pay $80 million upfront to obtain global rights to a clinic-ready cancer therapy from China-based Genhouse Bio. Headquartered in Suzhou, Genhouse Bio has been advancing its...

Results from the Phase III KALOS and LOGOS trials evaluating AstraZeneca Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF (320/28.8/9.6μg)) in patients with uncontrolled asthma have been published in The Lancet Respiratory Medicine, reporting statistically significant and clinically meaningful improvements compared...

The global pharmaceutical industry is entering a pivotal phase in obesity therapeutics as companies accelerate the transition from injectable GLP-1 drugs to oral weight-loss treatments, a shift expected to significantly expand patient access, alter reimbursement dynamics, and intensify competitive...

An aging population is reshaping medicine. Why pharma must redesign drug development, trials, and coverage strategies to meet the real needs of patients 65+. Some may think that seniors are aging out of the healthcare system, however it’s quite the...